Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases
NCT ID: NCT07161193
Last Updated: 2025-09-08
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
NOT_YET_RECRUITING
Clinical Phase
PHASE1/PHASE2
Total Enrollment
30 participants
Study Classification
INTERVENTIONAL
Study Start Date
2025-09-30
Study Completion Date
2027-11-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The goal of this study is to evaluate the safety and efficacy of CD19 CAR T cells in the treatment of Refractory Autoimmune Diseases
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases
NCT06688799
Autoimmune Diseases
RECRUITING
PHASE1/PHASE2
Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease
NCT06056921
SLE (Systemic Lupus)
Sjogren's Syndrome
Systemic Scleroderma
+2 more
RECRUITING
PHASE1
CAR-T Therapy for Refractory Autoimmune Diseases
NCT07059169
Autoimmune Diseases
NOT_YET_RECRUITING
NA
A Study of CD19 UCAR-T Cells in Subjects With Autoimmune Diseases
NCT07212322
Systemic Lupus Erythematosus
Idiopahic Inflammatory Myopathies
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
+4 more
NOT_YET_RECRUITING
NA
A Study of CAR-T Cells in Subjects with Autoimmune Diseases
NCT06762119
Autoimmune Diseases
NOT_YET_RECRUITING
EARLY_PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a single-center, open-label, single-arm, dose-escalation trial. In this study, we will recruit seven kinds of refractory autoimmune diseases including moderate-to-severe Systemic lupus erythematosus (SLE), refractory Pemphigus, refractory Idiopathic inflammatory myopathy (IIM), Systemic sclerosis (SSc), Refractory ANCA-Associated Vasculitis/Nephritis,refractory Rheumatoid arthritis(RA) and moderate-to-severe refractory Psoriasis.
Patients with Refractory Autoimmune Diseases will receive CD19 CAR T cells. The primary objective is to evaluate the safety and efficacy of CD19 CAR T cell therapy in subjects with Refractory Autoimmune Diseases and to determine the optimal biological dose (OBD) in phase I and to learn about the efficacy CD19 CAR T-cell therapy in patients with Refractory Autoimmune Diseases in phase II.
The primary endpoint is to evaluate the incidence and severity of cytokine release syndrome and severe neurotoxic adverse events within 28 days after CAR-T cell infusion.A total number of 3o subjects will be enrolled.
Patients with Refractory Autoimmune Diseases will receive CD19 CAR T cells. The primary objective is to evaluate the safety and efficacy of CD19 CAR T cell therapy in subjects with Refractory Autoimmune Diseases and to determine the optimal biological dose (OBD) in phase I and to learn about the efficacy CD19 CAR T-cell therapy in patients with Refractory Autoimmune Diseases in phase II.
The primary endpoint is to evaluate the incidence and severity of cytokine release syndrome and severe neurotoxic adverse events within 28 days after CAR-T cell infusion.A total number of 3o subjects will be enrolled.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Autoimmune Diseases
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental :CD19 CAR
Following the lymphodepleting treatment, patients will be treated with CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
Group Type
EXPERIMENTAL
CD19 CAR-T cells
Intervention Type
BIOLOGICAL
Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CD19 CAR-T cells
Following lymphodepletion with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with CD19 Chimeric Antigen Receptor (CAR) positive T cells as a single dose.
Intervention Type
BIOLOGICAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 1.Refractory Moderate-to-Severe Systemic lupus erythematosus (SLE) 1.1.Age 18-70 years. 1.2.Estimated life expectancy ≥ 3 months. 1.3.Documented disease history and diagnosis for ≥ 6 months prior to screening. 1.4.Participants must agree to use effective contraception throughout the study; women of child-bearing potential must have a negative pregnancy test.
1.5.Signed informed consent, agreement to the treatment protocol, and willingness to attend follow-up evaluations per schedule.
1.6.Relevant medical history and clinical manifestations: provide a copy of inpatient records from a tertiary hospital or outpatient records and diagnostic certificates within the last 3 months.
1.7.Required laboratory tests, including but not limited to: CBC, urinalysis, ANA, anti-dsDNA, ENA panel, C3/C4, immunoglobulins, antiphospholipid antibodies, etc.
1.8.Meets current international or domestic classification criteria: the 1997 ACR SLE classification criteria OR the 2019 EULAR/ACR SLE classification criteria, and is judged to have moderate-to-severe SLE.
1.9.SELENA-SLEDAI score ≥ 8; PGA ≥ 1; and at least one BILAG-2004 organ-system score of 1A or 2B.
1.10.Inadequate response to, or intolerance of, at least 12 weeks of standardized therapy prior to screening.
2.Refractory Idiopathic inflammatory myopathy (IIM) 2.1.Age 18-70 years. 2.2.Estimated life expectancy ≥ 3 months. 2.3.Documented disease history and diagnosis for ≥ 6 months prior to screening. 2.4.Participants must agree to use effective contraception throughout the study; women of child-bearing potential must have a negative pregnancy test.
2.5.Signed informed consent, agreement to the treatment protocol, and willingness to attend follow-up evaluations per schedule.
2.6.Relevant medical history and clinical manifestations: provide a copy of inpatient records from a tertiary hospital or outpatient records and diagnostic certificates within the last 3 months.
2.7.Fulfillment of the 2017 EULAR/ACR classification criteria for dermatomyositis or polymyositis.
2.8.Inadequate response to, or intolerance of, at least 12 weeks of standardized therapy prior to screening.
3.Refractory Systemic sclerosis (SSc) 3.1.Age 18-70 years. 3.2.Estimated life expectancy ≥ 3 months. 3.3.Documented disease history and diagnosis for ≥ 6 months prior to screening. 3.4.Participants must agree to use effective contraception throughout the study; women of child-bearing potential must have a negative pregnancy test.
3.5.Signed informed consent, agreement to the treatment protocol, and willingness to attend follow-up evaluations per schedule.
3.6.Relevant medical history and clinical manifestations: provide a copy of inpatient records from a tertiary hospital or outpatient records and diagnostic certificates within the last 3 months.
3.7.Fulfillment of the 2013 ACR/EULAR classification criteria for systemic sclerosis, with clinical or radiographic evidence of pulmonary involvement.
3.8.Required laboratory tests, including but not limited to: CBC, urinalysis, ANA, anti-dsDNA, ENA panel, C3/C4, immunoglobulins, etc.
3.9.Classification per current international or domestic standards: the 1980 ACR criteria for SSc OR the 2013 ACR/EULAR criteria for SSc.
3.10.Inadequate response to, or intolerance of, at least 12 weeks of standardized therapy prior to screening.
4.Refractory Pemphigus 4.1.Age 18-70 years. 4.2.Estimated life expectancy ≥ 3 months. 4.3.Documented disease history and diagnosis for ≥ 6 months prior to screening. 4.4.Participants must agree to use effective contraception throughout the study; women of child-bearing potential must have a negative pregnancy test.
4.5.Signed informed consent, agreement to the treatment protocol, and willingness to attend follow-up evaluations per schedule.
4.6.Relevant medical history and clinical manifestations: provide a copy of inpatient records from a tertiary hospital or outpatient records and diagnostic certificates within the last 3 months.
4.7.Fulfillment of at least one clinical manifestation plus one histopathological or immunodiagnostic criterion, OR at least two clinical manifestations plus two immunodiagnostic criteria:
* Clinical manifestations: flaccid cutaneous bullae and fragile blisters that rupture easily, resulting in persistent erosions; mucosal blisters or erosions; positive Nikolsky sign.
* Histopathology: intraepidermal or intraepithelial acantholysis.
* Immunodiagnostic criteria: direct immunofluorescence (DIF) showing intercellular IgG and/or complement deposition in epidermal/epithelial cells of lesional or perilesional normal skin; positive serum anti-epithelial cell antibodies by indirect immunofluorescence; positive serum anti-desmoglein antibodies by ELISA.
4.8.Pemphigus Disease Area Index (PDAI) ≥ 9 (moderate 9-24, severe ≥ 25). 4.9.Inadequate response to, or intolerance of, at least 12 weeks of standardized therapy prior to screening.
5.Refractory Moderate-to-Severe Psoriasis 5.1.Age 18-70 years. 5.2.Estimated life expectancy ≥ 3 months. 5.3.Documented disease history and diagnosis for ≥ 6 months prior to screening. 5.4.Participants must agree to use effective contraception throughout the study; women of child-bearing potential must have a negative pregnancy test.
5.5.Signed informed consent, agreement to the treatment protocol, and willingness to attend follow-up evaluations per schedule.
5.6.Relevant medical history and clinical manifestations: provide a copy of inpatient records from a tertiary hospital or outpatient records and diagnostic certificates within the last 3 months.
5.7.In accordance with the 2023 Chinese Guidelines for the Diagnosis and Treatment of Psoriasis, meets the diagnostic criteria for moderate-to-severe plaque psoriasis: dark-red or infiltrated erythematous plaques covered by white/silvery scales, demonstrating the wax-drip, film, and Auspitz signs.
5.8.At screening: Body Surface Area (BSA) involvement ≥ 10%, Psoriasis Area and Severity Index (PASI) ≥ 10, and static Physician's Global Assessment (sPGA) ≥ 3.
5.9.Inadequate response to, or intolerance of, at least 12 weeks of standardized therapy prior to screening.
6.Refractory Moderate-to-Severe Rheumatoid Arthritis 6.1.Age 18-70 years. 6.2.Estimated life expectancy ≥ 3 months. 6.3.Documented disease history and diagnosis for ≥ 6 months prior to screening. 6.4.Participants must agree to use effective contraception throughout the study; women of child-bearing potential must have a negative pregnancy test.
6.5.Signed informed consent, agreement to the treatment protocol, and willingness to attend follow-up evaluations per schedule.
6.6.Relevant medical history and clinical manifestations: provide a copy of inpatient records from a tertiary hospital or outpatient records and diagnostic certificates within the last 3 months.
6.7.Required laboratory and imaging assessments, including but not limited to: ESR, CRP, rheumatoid factor, ANA, anti-CCP antibodies, and other relevant autoantibodies; bilateral hand/foot radiographs.
6.8.Meets current international or domestic classification criteria: the 1987 ACR criteria for RA OR the 2010 ACR/EULAR criteria for RA.
6.9.Inadequate response to, or intolerance of, at least 12 weeks of standardized therapy prior to screening.
7.Refractory ANCA-Associated Vasculitis/Nephritis 7.1.Age 18-70 years. 7.2.Estimated life expectancy ≥ 3 months. 7.3.Documented disease history and diagnosis for ≥ 6 months prior to screening. 7.4.Participants must agree to use effective contraception throughout the study; women of child-bearing potential must have a negative pregnancy test.
7.5.Signed informed consent, agreement to the treatment protocol, and willingness to attend follow-up evaluations per schedule.
7.6.Relevant medical history and clinical manifestations: provide a copy of inpatient records from a tertiary hospital or outpatient records and diagnostic certificates within the last 3 months.
7.7.Meets the 2022 ACR/EULAR classification criteria for vasculitis. 7.8.Renal biopsy indicating kidney involvement, or clinical manifestations consistent with small-vessel vasculitis together with positive myeloperoxidase (MPO) or proteinase-3 (PR3) antibodies.
7.9.Persistent or newly emerging renal and/or systemic vasculitic manifestations despite maintenance therapy of the same intensity as initial immunosuppressive treatment.
7.10.Inadequate response to, or intolerance of, at least 12 weeks of standardized therapy prior to screening.
1.5.Signed informed consent, agreement to the treatment protocol, and willingness to attend follow-up evaluations per schedule.
1.6.Relevant medical history and clinical manifestations: provide a copy of inpatient records from a tertiary hospital or outpatient records and diagnostic certificates within the last 3 months.
1.7.Required laboratory tests, including but not limited to: CBC, urinalysis, ANA, anti-dsDNA, ENA panel, C3/C4, immunoglobulins, antiphospholipid antibodies, etc.
1.8.Meets current international or domestic classification criteria: the 1997 ACR SLE classification criteria OR the 2019 EULAR/ACR SLE classification criteria, and is judged to have moderate-to-severe SLE.
1.9.SELENA-SLEDAI score ≥ 8; PGA ≥ 1; and at least one BILAG-2004 organ-system score of 1A or 2B.
1.10.Inadequate response to, or intolerance of, at least 12 weeks of standardized therapy prior to screening.
2.Refractory Idiopathic inflammatory myopathy (IIM) 2.1.Age 18-70 years. 2.2.Estimated life expectancy ≥ 3 months. 2.3.Documented disease history and diagnosis for ≥ 6 months prior to screening. 2.4.Participants must agree to use effective contraception throughout the study; women of child-bearing potential must have a negative pregnancy test.
2.5.Signed informed consent, agreement to the treatment protocol, and willingness to attend follow-up evaluations per schedule.
2.6.Relevant medical history and clinical manifestations: provide a copy of inpatient records from a tertiary hospital or outpatient records and diagnostic certificates within the last 3 months.
2.7.Fulfillment of the 2017 EULAR/ACR classification criteria for dermatomyositis or polymyositis.
2.8.Inadequate response to, or intolerance of, at least 12 weeks of standardized therapy prior to screening.
3.Refractory Systemic sclerosis (SSc) 3.1.Age 18-70 years. 3.2.Estimated life expectancy ≥ 3 months. 3.3.Documented disease history and diagnosis for ≥ 6 months prior to screening. 3.4.Participants must agree to use effective contraception throughout the study; women of child-bearing potential must have a negative pregnancy test.
3.5.Signed informed consent, agreement to the treatment protocol, and willingness to attend follow-up evaluations per schedule.
3.6.Relevant medical history and clinical manifestations: provide a copy of inpatient records from a tertiary hospital or outpatient records and diagnostic certificates within the last 3 months.
3.7.Fulfillment of the 2013 ACR/EULAR classification criteria for systemic sclerosis, with clinical or radiographic evidence of pulmonary involvement.
3.8.Required laboratory tests, including but not limited to: CBC, urinalysis, ANA, anti-dsDNA, ENA panel, C3/C4, immunoglobulins, etc.
3.9.Classification per current international or domestic standards: the 1980 ACR criteria for SSc OR the 2013 ACR/EULAR criteria for SSc.
3.10.Inadequate response to, or intolerance of, at least 12 weeks of standardized therapy prior to screening.
4.Refractory Pemphigus 4.1.Age 18-70 years. 4.2.Estimated life expectancy ≥ 3 months. 4.3.Documented disease history and diagnosis for ≥ 6 months prior to screening. 4.4.Participants must agree to use effective contraception throughout the study; women of child-bearing potential must have a negative pregnancy test.
4.5.Signed informed consent, agreement to the treatment protocol, and willingness to attend follow-up evaluations per schedule.
4.6.Relevant medical history and clinical manifestations: provide a copy of inpatient records from a tertiary hospital or outpatient records and diagnostic certificates within the last 3 months.
4.7.Fulfillment of at least one clinical manifestation plus one histopathological or immunodiagnostic criterion, OR at least two clinical manifestations plus two immunodiagnostic criteria:
* Clinical manifestations: flaccid cutaneous bullae and fragile blisters that rupture easily, resulting in persistent erosions; mucosal blisters or erosions; positive Nikolsky sign.
* Histopathology: intraepidermal or intraepithelial acantholysis.
* Immunodiagnostic criteria: direct immunofluorescence (DIF) showing intercellular IgG and/or complement deposition in epidermal/epithelial cells of lesional or perilesional normal skin; positive serum anti-epithelial cell antibodies by indirect immunofluorescence; positive serum anti-desmoglein antibodies by ELISA.
4.8.Pemphigus Disease Area Index (PDAI) ≥ 9 (moderate 9-24, severe ≥ 25). 4.9.Inadequate response to, or intolerance of, at least 12 weeks of standardized therapy prior to screening.
5.Refractory Moderate-to-Severe Psoriasis 5.1.Age 18-70 years. 5.2.Estimated life expectancy ≥ 3 months. 5.3.Documented disease history and diagnosis for ≥ 6 months prior to screening. 5.4.Participants must agree to use effective contraception throughout the study; women of child-bearing potential must have a negative pregnancy test.
5.5.Signed informed consent, agreement to the treatment protocol, and willingness to attend follow-up evaluations per schedule.
5.6.Relevant medical history and clinical manifestations: provide a copy of inpatient records from a tertiary hospital or outpatient records and diagnostic certificates within the last 3 months.
5.7.In accordance with the 2023 Chinese Guidelines for the Diagnosis and Treatment of Psoriasis, meets the diagnostic criteria for moderate-to-severe plaque psoriasis: dark-red or infiltrated erythematous plaques covered by white/silvery scales, demonstrating the wax-drip, film, and Auspitz signs.
5.8.At screening: Body Surface Area (BSA) involvement ≥ 10%, Psoriasis Area and Severity Index (PASI) ≥ 10, and static Physician's Global Assessment (sPGA) ≥ 3.
5.9.Inadequate response to, or intolerance of, at least 12 weeks of standardized therapy prior to screening.
6.Refractory Moderate-to-Severe Rheumatoid Arthritis 6.1.Age 18-70 years. 6.2.Estimated life expectancy ≥ 3 months. 6.3.Documented disease history and diagnosis for ≥ 6 months prior to screening. 6.4.Participants must agree to use effective contraception throughout the study; women of child-bearing potential must have a negative pregnancy test.
6.5.Signed informed consent, agreement to the treatment protocol, and willingness to attend follow-up evaluations per schedule.
6.6.Relevant medical history and clinical manifestations: provide a copy of inpatient records from a tertiary hospital or outpatient records and diagnostic certificates within the last 3 months.
6.7.Required laboratory and imaging assessments, including but not limited to: ESR, CRP, rheumatoid factor, ANA, anti-CCP antibodies, and other relevant autoantibodies; bilateral hand/foot radiographs.
6.8.Meets current international or domestic classification criteria: the 1987 ACR criteria for RA OR the 2010 ACR/EULAR criteria for RA.
6.9.Inadequate response to, or intolerance of, at least 12 weeks of standardized therapy prior to screening.
7.Refractory ANCA-Associated Vasculitis/Nephritis 7.1.Age 18-70 years. 7.2.Estimated life expectancy ≥ 3 months. 7.3.Documented disease history and diagnosis for ≥ 6 months prior to screening. 7.4.Participants must agree to use effective contraception throughout the study; women of child-bearing potential must have a negative pregnancy test.
7.5.Signed informed consent, agreement to the treatment protocol, and willingness to attend follow-up evaluations per schedule.
7.6.Relevant medical history and clinical manifestations: provide a copy of inpatient records from a tertiary hospital or outpatient records and diagnostic certificates within the last 3 months.
7.7.Meets the 2022 ACR/EULAR classification criteria for vasculitis. 7.8.Renal biopsy indicating kidney involvement, or clinical manifestations consistent with small-vessel vasculitis together with positive myeloperoxidase (MPO) or proteinase-3 (PR3) antibodies.
7.9.Persistent or newly emerging renal and/or systemic vasculitic manifestations despite maintenance therapy of the same intensity as initial immunosuppressive treatment.
7.10.Inadequate response to, or intolerance of, at least 12 weeks of standardized therapy prior to screening.
Exclusion Criteria
* (1) Clinically significant (as determined by the investigator) history of cardiac, endocrine, pulmonary, neurologic, psychiatric, hepatic, renal, hematologic, immunologic, or other major diseases.
(2) Pregnant or lactating women. (3) History of active tuberculosis (TB) infection within 3 years prior to the screening visit.
(4) History of traumatic brain injury, altered consciousness, epilepsy, cerebral ischemia, or any cerebrovascular hemorrhagic disorders.
(5) Prolonged QT interval on ECG or history of severe arrhythmias or other significant cardiac disorders.
(6) Active infection (excluding uncomplicated urinary tract infection and bacterial pharyngitis).
(7) Active hepatitis B virus or hepatitis C virus infection. (8) Confirmed positive anti-HIV antibody test. (9) Positive Treponema pallidum antibody test judged by the investigator to be clinically significant.
(10) Any known or suspected congenital or acquired immunodeficiency that may compromise the subject's immune status.
(11) Prior treatment with CD19 CAR-T cell therapy or CD19-targeted antibody drugs.
(12) Prior exposure to any gene therapy. (13) ALT/AST \> 3× ULN, or bilirubin \> 2.0× ULN, or serum creatinine \> 2× ULN, or creatinine clearance \< 30 mL/min.
(14) Any condition that, in the opinion of the investigator, may increase patient risk or interfere with study results.
(2) Pregnant or lactating women. (3) History of active tuberculosis (TB) infection within 3 years prior to the screening visit.
(4) History of traumatic brain injury, altered consciousness, epilepsy, cerebral ischemia, or any cerebrovascular hemorrhagic disorders.
(5) Prolonged QT interval on ECG or history of severe arrhythmias or other significant cardiac disorders.
(6) Active infection (excluding uncomplicated urinary tract infection and bacterial pharyngitis).
(7) Active hepatitis B virus or hepatitis C virus infection. (8) Confirmed positive anti-HIV antibody test. (9) Positive Treponema pallidum antibody test judged by the investigator to be clinically significant.
(10) Any known or suspected congenital or acquired immunodeficiency that may compromise the subject's immune status.
(11) Prior treatment with CD19 CAR-T cell therapy or CD19-targeted antibody drugs.
(12) Prior exposure to any gene therapy. (13) ALT/AST \> 3× ULN, or bilirubin \> 2.0× ULN, or serum creatinine \> 2× ULN, or creatinine clearance \< 30 mL/min.
(14) Any condition that, in the opinion of the investigator, may increase patient risk or interfere with study results.
Minimum Eligible Age
18 Years
Maximum Eligible Age
70 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Second Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
UNKNOWN
Sponsor Role
collaborator
Henan Province Engineering Technology Research Center of Immunological Precision Medicine and Artificial Intelligence Application, Luoyang, China
UNKNOWN
Sponsor Role
collaborator
Hebei Senlang Biotechnology Inc., Ltd.
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Huirui Wang, M.D.
Role: PRINCIPAL_INVESTIGATOR
Henan Province Engineering Technology Research Center of Immunological Precision Medicine and Artificial Intelligence Application, The Second Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Henan Province Engineering Technology Research Center of Immunological Precision Medicine and Artificial Intelligence Application, The Second Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
Luoyang, Henan, China
Site Status
Countries
Review the countries where the study has at least one active or historical site.
China
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
L2025021-2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
CD19-BAFF CAR-T Cells Therapy for Patients With Autoimmune Diseases
NCT06279923
RECRUITING
EARLY_PHASE1
Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined with Immunosuppressants in the Treatment of Refractory Autoimmune Diseases
NCT06821659
NOT_YET_RECRUITING
PHASE1/PHASE2
Autologous CD19CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases
NCT06993493
RECRUITING
NA
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research
NCT06711146
RECRUITING
EARLY_PHASE1
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
NCT06794008
RECRUITING
PHASE2
Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases
NCT06939166
RECRUITING
EARLY_PHASE1
Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus
NCT06222853
ACTIVE_NOT_RECRUITING
PHASE1
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
NCT07331467
RECRUITING
PHASE1
CAR T Cells for Refractory B Cell Malignancy
NCT02963038
UNKNOWN
PHASE1/PHASE2
A Study of CAR-T Cells Targeting Autoimmune Diseases
NCT06661811
NOT_YET_RECRUITING
NA
Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases
NCT06316076
RECRUITING
PHASE1
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus
NCT05030779
UNKNOWN
EARLY_PHASE1
A Study of CAR-T Cells in Subjects With Autoimmune Diseases
NCT07040917
NOT_YET_RECRUITING
EARLY_PHASE1
Safety and Efficacy of CD19 CAR-T Therapy for Recurrent/Refractory Autoimmune Diseases
NCT06983964
RECRUITING
NA
Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE
NCT06892145
RECRUITING
PHASE1
To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors
NCT05388695
RECRUITING
PHASE1
CD19/BCMA CAR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus
NCT06349343
RECRUITING
PHASE1
Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease
NCT06373081
RECRUITING
NA
CD19-CAR-T in B-cell Malignancies Patients
NCT03952923
COMPLETED
PHASE1
A Study of OL-CD19-GDT in Relapsed/ Refractory Autoimmune Diseases
NCT07167537
RECRUITING
PHASE1
Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
NCT06548607
RECRUITING
EARLY_PHASE1
CAR-T Cells Targeting Autoimmune Diseases
NCT05459870
RECRUITING
PHASE1/PHASE2
Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases
NCT06549296
SUSPENDED
EARLY_PHASE1
Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE
NCT07233642
RECRUITING
PHASE1
CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
NCT02965092
UNKNOWN
PHASE1/PHASE2